Why the study?
Does genotype influence structural atrial abnormalities and the occurrence of atrial arrhythmias in patients with ARVD/C?
Cohort (n=111)
Does genotype influence structural atrial abnormalities and the occurrence of atrial arrhythmias in patients with ARVD/C?
Genotype influences atrial volume and the occurrence of atrial arrhythmias in ARVD/C, with PKP2 mutation carriers exhibiting significantly smaller atria despite a similar incidence of arrhythmias compared to those without identified mutations.
INTRODUCTION: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is associated with desmosomal mutations. Although desmosomal disruption affects both ventricles and atria, little is known about atrial involvement in ARVD/C. OBJECTIVE: To describe the extent and clinical significance of structural atrial involvement and atrial arrhythmias (AA) in ARVD/C stratified by genotype. METHODS: We included 71 patients who met ARVD/C Task Force Criteria and underwent cardiac magnetic resonance (CMR) imaging and molecular genetic analysis. Indexed atrial end-diastolic volume and area-length-ejection-fraction (ALEF) were evaluated on CMR and compared to controls with idiopathic right ventricular outflow tract tachycardia (n = 40). The primary outcome was occurrence of AA (atrial fibrillation or atrial flutter) during follow-up, recorded by 12-lead ECG, Holter monitoring or implantable cardioverter defibrillator (ICD) interrogation. RESULTS: Patients harbored a desmosomal plakophilin-2 (PKP2) (n = 37) or nondesmosomal phospholamban (PLN) (n = 14) mutation. In 20 subjects, no pathogenic mutation was identified. Compared to controls, right atrial (RA) volumes were reduced in PKP2 (P = 0.002) and comparable in PLN (P = 0.441) mutation carriers. In patients with no mutation identified, RA (P = 0.011) and left atrial (P = 0.034) volumes were increased. Bi-atrial ALEF showed no significant difference between the groups. AA were experienced by 27% of patients and occurred equally among PKP2 (30%) and no mutation identified patients (30%), but less among PLN mutation carriers (14%). CONCLUSION: Genotype influences atrial volume and occurrence of AA in ARVD/C. While the incidence of AA is similar in PKP2 mutation carriers and patients with no mutation identified, PKP2 mutation carriers have significantly smaller atria. This suggests a different arrhythmogenic mechanism.
No takes yet. Share an insight, caveat, or question.
Bourfiss et al. (2016) conducted a cohort in Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) (n=111). ARVD/C genotype (PKP2, PLN, or no mutation) vs. Controls with idiopathic right ventricular outflow tract tachycardia was evaluated on Occurrence of atrial arrhythmias (atrial fibrillation or atrial flutter) during follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: